Various studies suggest ␣ 2 -adrenergic receptor ( ␣ 2 AR) dysregulation in panic disorder (PD). Platelet
Evidence for abnormal ␣ 2 -adrenergic receptor ( ␣ 2 AR) function in panic disorder (PD) derives from cardiovascular, neuroendocrine, and neurochemical challenges, and from direct receptor binding studies. Cardiovascular responses to an acute intravenous clonidine challenge, a partial ␣ 2 AR agonist, were exaggerated in PD (Nutt 1986) , consistent with postsynaptic AR supersensitivity. 3-Methoxy-4-hydroxyphenylethylene glycol (MHPG) and cardiovascular responses to acute yohimbine administration were higher in PD patients than in controls (Charney and Heninger 1986; Gurguis and Uhde 1990) , despite normal norepinephrine (NE) responses (Albus et al. 1992; Gurguis et al. 1997c) . Collectively, enhanced cardiovascular responses, despite normal NE responses, suggest increased postsynaptic end-organ vascular ␣ 2 AR function.
Neuroendocrine challenge studies in PD used clonidine as a probe of hypothalamic ␣ 2 AR function. Growth hormone response to clonidine in PD was blunted in virtually all studies (Charney and Heninger 1986; Uhde et al. 1986; Nutt 1989; Abelson et al. 1992) , suggesting decreased hypothalamic ␣ 2 AR function (Siever et al. 1982; Siever and Uhde 1984) . However, blunted growth hormone response to growth hormone-releasing factor in PD suggests alternative etiologies to decreased ␣ 2 AR function (Rapaport et al. 1989; Uhde et al. 1992; Tancer et al. 1993) .
Platelet ␣ 2 AR receptor binding studies in PD yield inconsistent results. Low platelet ␣ 2 AR density was found using 3 H-yohimbine, but not 3 H-clonidine, in PD patients, and imipramine treatment increased or normalized receptor density (Cameron et al. 1984) . Low 3 H-yohimbine and/or 3 H-clonidine maximum binding capacity was later replicated in PD and in generalized anxiety disorder (Albus et al. 1986; Cameron et al. 1990 Cameron et al. , 1996 . Other studies found normal ␣ 2 AR density in PD (Norman et al. 1987; Nutt and Fraser 1987; Charney et al. 1989 ). However, low EC 50 for epinephrine inhibition of adenylyl cyclase (AC) and low PGE 1 -and NaFl-stimulated AC activity was found (Charney et al. 1989 ). The latter observations suggest either increased receptor density, high ␣ 2 AR coupling to G i protein, abnormal G i protein function, or abnormal G i ␣ -AC interaction. Finally, high ␣ 2 AR density and the lack of antidepressant treatment effect on ␣ 2 AR density in PD was also reported (Butler et al. 1992) . Therefore, evidence suggests abnormal ␣ 2 AR regulation in PD, although the nature of this dysregulation is unclear.
Platelet ␣ 2 AR, similar to brain ␣ 2 AR, are of the C10 subtype (previously classified as ␣ 2A ) (Lorenz et al. 1990; Bylund et al. 1992; Ordway et al. 1993) . Platelet membrane ␣ 2 AR belong to a superfamily of G proteincoupled receptors. The receptor molecule (450 amino acids) has seven transmembrane spanning domains. The fourth transmembrane spanning domain is involved in ligand binding (Matsui et al. 1989) , and the third intracytoplasmic loop is the site for G protein coupling and receptor phosphorylation. Platelet ␣ 2 AR are coupled to G i protein (Simonds et al. 1989) . They exist in high-and low-conformational states as a function of their coupling to G i protein upon agonist binding (Kim and Neubig 1987; Neubig et al. 1988) . Inhibition of AC is mediated by the high-conformational state (Hoffman et al. 1980; Thomsen et al. 1988) . Coupling to G i protein is an important step in the signal transduction cascade.
The ternary receptor model (DeLean et al. 1980 (DeLean et al. , 1982 Kent et al. 1980) suggests that the formation of the highconformational state is a transitory (intermediate) agonist-receptor-G protein complex, which precedes the activation of G i protein and the dissociation of the G i ␣ from the inactive ␣␤␥ holotrimer G i molecule. The G i ␣ subunit subsequently inhibits AC. Consistent with this model, the percentage of receptors in the high-conformational state (%R H ) and the ratio of the agonist dissociation constant from the receptor in the low-/high-conformational states (K L /K H ratio) correlate with the agonist's intrinsic activity (DeLean et al. 1980 (DeLean et al. , 1982 Kent et al. 1980; Hoffman et al. 1982) . These two measures have been proposed as putative measures of receptor coupling to G protein.
Virtually all ␣ 2 AR binding studies in PD have measured the maximum binding capacity of the ligand (B max ). They have not examined ␣ 2 AR coupling, the relative distribution of receptors in the high-and low-conformational states, or agonist affinity to the receptor in either conformational state. In addition to downregulating receptor density (Salama et al. 1982; Smith et al. 1983; Keith et al. 1986; Giralt and García-Sevilla 1989; Lacroix et al. 1991; Kovachich et al. 1993; Ribas et al. 1993; Moret and Briley 1994) , tricyclic antidepressants have been shown to modulate AR coupling through mechanisms directly influencing postreceptor signal transduction; specifically, G protein function and G protein-AC interaction (Okada et al. 1986; Fishman and Finberg 1987; Tsuchiya et al. 1988; Yamamoto et al. 1990 ). The efficacy of tricyclic antidepressants in PD also raises the possibility of abnormal ␣ 2 AR coupling, and, secondarily, of whether antidepressant modulation of ␣ 2 AR coupling by antidepressants is related to treatment outcome.
In this study we investigated platelet ␣ 2 AR function in 21 PD patients and 21 healthy controls. We conducted both antagonist-saturation and agonist (NE)-displacement experiments on platelet membranes from all subjects. Coupling indices were derived from agonist displacement curves. Radioreceptor binding experiments were repeated in eight of the 21 PD patients after treatment with imipramine at therapeutically effective doses, as ascertained by plasma imipramine levels. Severity of anxiety and depressive symptoms was assessed before and after treatment to determine whether treatment outcome was influenced by the nature of dysregulation in pretreatment ␣ 2 AR. We hypothesized that ␣ 2 AR density and coupling are abnormal in PD. We further hypothesized that treatment with antidepressants induces downregulatoin of ␣ 2 AR density and modulates ␣ 2 AR coupling to G i protein.
METHODS

Subjects
Platelet ␣ 2 AR were investigated in 21 male patients with PD, with or without agoraphobia, and in 21 healthy controls. Patients were recruited from the Mental Health Clinic at the Dallas VA Medical Center. Patients met DSM-III-R (APA 1987) diagnostic criteria for PD with or without agoraphobia. None of the patients met diagnostic criteria for concurrent major depression or had a history of a major depressive episode within the previ-N EUROPSYCHOPHARMACOLOGY 1999 -VOL . 20 , NO . 2 ous 6 months. Diagnosis was made using a comprehensive semistructured clinical interview (GNMG).
Frequency of unexpected and situational panic attacks per week and severity of anticipatory anxiety were obtained from patients using a daily diary. Severity of anticipatory anxiety was defined as the percent of time awake that the patient is preoccupied with fear of having a panic attack or fear of entering a situation likely to trigger an attack, multiplied by the severity (on a 0 to 10 scale) of that fear. The product of these two factors was divided by 10 to obtain a final score on a 0 to 100 scale.
Healthy controls were gender-and age-matched with patients and had no personal or familial psychiatric history. Patients and controls were drug-free for at least 2 weeks (6 weeks in the case of serotonin reuptake inhibitors) before the study. Subjects had no current medical complaints and were physically healthy, as ascertained by medical history, physical examination, and laboratory work-up. Subjects observed a low-monoamine and restricted-caffeine diet for 3 days before blood sample collection. The study was approved by the Human Subjects Committee at the Dallas VA Medical Center, and all subjects signed an informed written consent form before participating in the study.
After baseline study, PD patients were treated with imipramine. Imipramine dosage was gradually increased to therapeutic levels, as verified by imipramine plasma levels. ␣ 2 AR were assayed after imipramine treatment in eight of the 21 patients.
Procedure
Subjects came to our laboratory at 7:30 A . M . on the procedure day, having observed an overnight fast and assumed a supine position in a hospital bed in a quiet room. An intravenous (IV) line was established (antecubital vein, nondominant arm). Subjects rested for 60 min following IV line placement. Sixty ml of blood were then drawn for receptor assay, and the IV line was discontinued.
Symptom ratings, including the Hamilton Scale for Anxiety (HAMA) Hamilton 1959), the Hamilton Scale for Depression (HAMD, 24-item) (Hamilton 1967), the Zung Anxiety Scale (both clinician-and self-rated; ZungC and ZungS, respectively) (Zung 1971) , the Spielberger-State Anxiety Inventory (SpS), the SpielbergerTrait) Anxiety Inventory (SpT) (Spielberger et al. 1970; Spielberger 1983 ) and 100-mm Visual Analog Scales (VAS) of mood (anxiety, tension, irritability, fearfulness, depression, and anger) and somatic autonomic anxiety symptoms, were completed by patients and controls after the procedure (Aitken and Gedye 1968; Aitken 1969; Zealley and Aitken 1969; Folstein and Luria 1973; Luria 1975 ).
Platelet ␣ 2 -Adrenergic Receptor Assay
Platelet ␣ 2 AR binding assays were conducted according to García-Sevilla et al. (1981a) , with modifications. Briefly, blood (60 ml) was drawn on acid citrate dextrose (ACD-NIH formula) and centrifuged (160 ϫ g for 10 min) at room temperature. Platelet-rich plasma was buffered using ACD to pH 6.5 and centrifuged at 5,100 ϫ g for 15 minutes. The platelet pellet was washed twice with Tyrodes buffer and recentrifuged at 5,100 ϫ g for 15 min. Platelets were then resuspended and homogenized using a Brinkman polytron at setting 5 for 15 s. Platelet membranes were obtained using differential centrifugation, and the membrane pellet was resuspended in the Tris-HCl incubation buffer (50 mM Tris-HCl; 10 mM MgCl 2 , pH 7.5). Fresh membrane preparations were used in the receptor binding experiments in all subjects.
Tritiated yohimbine (SA 70-90 Ci/mmol) was used as a ligand. Saturation experiments were conducted using seven 3 H-yohimbine concentrations (0.25-16.0 nM). Nonspecific binding was defined in the presence of norepinephrine (0.1 mM). Specific binding, defined as total binding minus nonspecific binding, was approximately 90%. Displacement experiments were conducted using 18 concentrations of "cold" NE (0-1.0 mM) to displace 3 H-yohimbine (2 nM). Samples were incubated at 25ЊC for 30 min. Incubation was terminated by rapid filtration over glassfiber filters #32 (Schleicher and Schuell, Keene, NH, USA) using a Brandel M-24R cell harvester (Brandel, Gaithersburg, MD, USA). Filters were airdried and placed in glass scintillation vials with 20 ml of scintillation cocktail for counting in a Tri-Carb CA2200 (Packard, Downer's Grove, Ill, USA), with 55 to 66% efficiency. Protein concentrations were measured (Lowry et al. 1951) .
Binding Data Analysis
Binding data were analyzed using LIGAND program Rodbard 1983, 1984) . LIGAND uses iterative curve-fitting methods based on the law of mass action. Scatchard analysis was used to analyze saturation binding experiments, using weighted curvilinear fitting techniques, with the dissociation constant equal to Ϫ1/ slope, and the maximum binding capacity representing the x-intercept. Analysis of displacement experiments employed nonlinear iterative curve-modeling methods that test for the presence of more than one binding state. An F-test was used to compare the goodness-of-fit between the two models. A two-site model was accepted only if the goodness-of-fit was statistically significantly better than the one-site model (p Ͻ .05).
The maximum binding capacity (B max ) and the antagonist dissociation constant from the receptor (K d ) were measured from saturation experiments. Receptor density in the high-(R H ) and low-(R L ) conformational states, and the agonist dissociation constant from the receptor in the high-(K H ) and low-(K L ) conformational states were measured from displacement curves. The total agonist-measured receptor density (R T , R T ϭ R H ϩ R L ), %R H , and K L /K H ratio were determined. %R H and the K L /K H ratio were used as putative indices of ␣ 2 AR coupling to G i protein. These receptor coupling measures correlate with the agonist's intrinsic activity (DeLean et al. 1980 (DeLean et al. , 1982 Kent et al. 1980) . See Figure 1 .
Statistical Analysis
Between-group differences (PD patients vs. healthy controls) in coupling measures (%R H and K L /K H ) and other receptor binding parameters were tested using two-tailed independent t-tests. One-way analysis of variance (ANOVA) was used in three-group comparisons. Two-tailed paired t-tests were used to compare pre-to post-treatment measures in patients. Finally, the relationships among symptom ratings and receptor binding parameters were tested before and after treatment, using Pearson's product moment analysis. To test if pretreatment receptor-binding parameters predicted symptom severity after treatment, we conducted regression analysis using pretreatment receptor-binding parameters as dependent variables and anxiety and depression severity ratings after treatment as independent variables. All data are presented as mean Ϯ SEM.
RESULTS
There was no significant difference in age between PD patients and healthy controls (PD: 42.05 Ϯ 1.82 years vs. NC: 41.33 Ϯ 2.35 years, t ϭ 0.240; p ϭ NS). Patients had an average of 4.8 unexpected panic attacks and 3.00 situational panic attacks per week, with mean anticipatory anxiety severity of 20 (0-100 scale). Table 1 shows characteristics of patients and controls.
Several measures of ␣ 2 AR density were higher in PD patients than in controls: B max (t ϭ 3.512, p ϭ .001), R H (t ϭ 3.648, p ϭ .001), R L (t ϭ 2.732, p ϭ .009), and R T (t ϭ 3.518, p ϭ .001). There was a trend for higher %R H in patients (t ϭ 1.740, p ϭ .09) and lower K L /K H ratio (t ϭ Ϫ1.804, p ϭ .08). The trend for lower K L /K H ratio appeared secondary to a moderately lower K H . There were no significant differences, however, between patients and controls in K H or K L .
To examine the effect of coexistence of depressed mood (albeit in absence of concurrent major depressive disorder), PD patients were subdivided into two groups based on their HAMD scores: "nondepressed" (HAMD score Ͻ15) and "depressed" (HAMD score у15). Table 2 shows results of the one-way ANOVA comparing each of the two groups to controls. Patients with HAMD scores у15 had significantly higher %R H (t ϭ 2.280, p ϭ .03) and lower K L /K H ratio (t ϭ 2.172, p ϭ .03) than controls. No significant differences, however, were observed between "nondepressed" PD patients and controls.
Eight PD patients received treatment with imipramine for an average length of 203 Ϯ 45 days. All eight patients were treated with imipramine at therapeutic plasma levels (imipramine: 125.5 Ϯ 16.65 ng/ml; desipramine: 124.13 Ϯ 13.99 ng/ml; total: 249.63 Ϯ 26.30 ng/ml). Paired analysis showed that treatment with imipramine had no effect on ␣ 2 AR binding parameters. A numeric increase in the K L /K H ratio was found, but it did not reach statistical significance. There was a significant decrease in the frequency of panic attacks at the end of treatment. However, the decrease in HAMA and HAMD scores was less than the conventionally acknowledged limit for a positive outcome, defined as a 50% decrease in severity of pretreatment symptoms. Finally, some sporadic somatic symptoms that seem to have worsened are likely side effects of imipramine ( Table 3) .
The following correlations between psychological ratings and ␣ 2 AR binding parameters were found.
Healthy Controls (n ϭ 21)
Age was negatively correlated with B max (r ϭ Ϫ0.375, p ϭ .09) and R H (r ϭ Ϫ0.380, p ϭ .09). K L /K H ratio was positively correlated with SpT (r ϭ 0.500, p ϭ .02). %R H was positively correlated with SpS (r ϭ 0.443, p ϭ .04). R H was positively correlated with VAS of tension (r ϭ 0.433, p ϭ .05) and anxiety (r ϭ 0.415, p ϭ .06), and with SpT (r ϭ 0.373, p ϭ .09). Both coupling measures, %R H and K L /K H , were positively correlated with severity of Figure 1 . A representative norepinephrine displacement curve of 3 H-yohimbine binding to platelet membrane ␣ 2 -adrenergic receptors in a panic disorder patient. Displacement curves were flat and were resolved into a two-site model. Estimates of receptor density in the high-and lowconformational states as well as agonist affinity to each conformational state were derived.
anxiety. There were no correlations between ␣ 2 AR binding parameters and VAS of somatic autonomic anxiety symptoms.
PD Patients Before Treatment (n ϭ 21)
Age was correlated with various measures of ␣ 2 AR density: B max (r ϭ 0.515, p ϭ .02), R H (r ϭ 0.449, p ϭ .04), R L (r ϭ 0.447, p ϭ .03) and R T (r ϭ 0.464, p ϭ .03). The K L /K H ratio correlated positively with the total number of panic attacks during the previous week (r ϭ 0.455, p ϭ .04) and negatively with HAMD score (r ϭ Ϫ0.603, p ϭ .004), SpS (r ϭ Ϫ0.458, p ϭ .04), and ZungC (r ϭ Ϫ0.796, p ϭ .03). %R H was positively correlated with HAMA score (r ϭ 0.443, p ϭ .04), HAMD score (r ϭ 0.509, p ϭ .02) and VAS of fearfulness (r ϭ 0.400, p ϭ .07), racing heart (r ϭ 0.596, p ϭ .004), and palpitations (r ϭ 0.411, p ϭ .04).
R H correlated negatively with severity of anticipatory anxiety (r ϭ Ϫ0.426, p ϭ .05) and positively with HAMD score (r ϭ 0.424, p ϭ .05), SpS (r ϭ 0.470, p ϭ .03), ZungC (r ϭ 0.881, p ϭ .009), and VAS of depression (r ϭ 0.433, p ϭ .05). R L was negatively correlated with severity of anticipatory anxiety (r ϭ Ϫ 0.410, p ϭ .06) Figure 3) .
Thus, the severity of anticipatory anxiety was negatively correlated with several measures of ␣ 2 AR binding density. Both coupling measures of ␣ 2 AR were correlated with several ratings of anxiety and depression, although in opposite directions. Psychological ratings were negatively correlated with the K L /K H ratio, but they were positively correlated with %R H . ␣ 2 AR parameters showed only scattered correlations with somatic autonomic anxiety symptoms, which did not suggest a consistent discernible pattern.
PD Patients After Treatment (n ϭ 8)
%R H was negatively correlated with VAS of shakiness (r ϭ Ϫ0.786, p ϭ .02) and palpitations (r ϭ Ϫ0.623, p ϭ .10). R H was negatively correlated with ZungS (r ϭ Ϫ0.694, p ϭ .05), SpT (r ϭ Ϫ0.676, p ϭ .07), and VAS of tension (r ϭ Ϫ0.652, p ϭ .08). R L correlated negatively with SpT (r ϭ Ϫ0.735, p ϭ .04) and ZungS (r ϭ Ϫ0.901, p ϭ .002) and positively with VAS of shakiness (r ϭ 0.642, p ϭ .08). R T was negatively correlated with SpT (r ϭ Ϫ0.754, p ϭ .03) and ZungS (r ϭ Ϫ0.855, p ϭ .007). B max was negatively correlated with SpT (r ϭ Ϫ0.777, p ϭ .02) and Zung S (r ϭ Ϫ0.872, p ϭ .005).
K d correlated negatively with VAS of anger (r ϭ Ϫ0.705, p ϭ .05). K H was negatively correlated with HAMD score (r ϭ Ϫ0.686, p ϭ .06). Post-treatment log K L was negatively correlated with VAS of shakiness (r ϭ Ϫ0.656, p ϭ .08), racing heart (r ϭ Ϫ0.875, p ϭ .004), palpitations (r ϭ Ϫ0.753, p ϭ .03), difficulty breathing (r ϭ Ϫ0.751, p ϭ .03), rapid breathing (r ϭ Ϫ0.771, p ϭ .02), dizziness (r ϭ Ϫ0.672, p ϭ .07), weakness in the muscles (r ϭ Ϫ0.706, p ϭ .05), numbness (r ϭ Ϫ0.727, p ϭ .04), choking (r ϭ Ϫ0.656, p ϭ .08), chest pain (r ϭ Ϫ0.681, p ϭ .06), hot flashes (r ϭ Ϫ0.727, p ϭ .04), nausea (r ϭ Ϫ0.756, p ϭ .03), and dry mouth (r ϭ Ϫ0.748, p ϭ .03).
Post-treatment correlations between ␣ 2 AR binding parameters and psychological ratings, particularly coupling measures, were only sporadic. In contrast to pretreatment correlations, where ␣ 2 AR binding parameters were not correlated with somatic anxiety symptoms, post-treatment K L showed moderately strong correlations with multiple measures of severity of somatic anxiety symptoms.
Results of the regression analysis (n ϭ 8) examining the relationship between pretreatment ␣ 2 AR binding parameters and severity of symptoms after treatment revealed the following. Pretreatment K L /K H ratio was negatively correlated with post-treatment number of unexpected panic attacks (r ϭ Ϫ0.688, p ϭ .06), number of total panic attacks (r ϭ Ϫ0.657, p ϭ .07), severity of anticipatory anxiety (r ϭ Ϫ0.754, p ϭ .03), HAMD score (r ϭ Ϫ0.733, p ϭ .04), and VAS of depression (r ϭ Ϫ0.674, p ϭ .07).
Pretreatment R H was negatively correlated with post-treatment VAS of anxiety (r ϭ Ϫ0.711, p ϭ .05), tension (r ϭ Ϫ0.826, p ϭ .01), palpitations (r ϭ Ϫ0.637, p ϭ .09), difficulty breathing (r ϭ Ϫ0.626, p ϭ .10), rapid breathing (r ϭ Ϫ0.623, p ϭ .10), and hot flashes (r ϭ Ϫ0.645, p ϭ .08). Pretreatment R L was negatively correlated with post-treatment SpS (r ϭ Ϫ0.782, p ϭ .02), SpT (r ϭ Ϫ0.911, p ϭ .002), ZungS (r ϭ Ϫ0.706, p ϭ .05), and VAS of anxiety (r ϭ Ϫ0.749, p ϭ .03), and tension (r ϭ Ϫ0.827, p ϭ .01). Pretreatment R T was negatively correlated with post-treatment SpS (r ϭ Ϫ0.651, p ϭ .08), SpT (r ϭ Ϫ0.712, p ϭ .05), and VAS of anxiety (r ϭ Ϫ0.759, p ϭ .03), and tension (r ϭ Ϫ0.870, p ϭ .005). Pretreatment B max was negatively correlated with post-treatment SpS (r ϭ Ϫ0.713, p ϭ .04), SpT (r ϭ Ϫ0.640, p ϭ .09), and VAS of anxiety (r ϭ Ϫ0.721, p ϭ .04), tension (r ϭ Ϫ0.852, p ϭ .007), and fearfulness (r ϭ Ϫ0.648, p ϭ .08).
Pretreatment K d was positively correlated with posttreatment number of unexpected panic attacks during the previous week (r ϭ 0.686, p ϭ .06), and with SpS (r ϭ 0.773, p ϭ .02). Pretreatment K H was negatively correlated with post-treatment VAS of shakiness (r ϭ Ϫ0.629, p ϭ .09) (See Figure 4, Figure 5 , and Figure 6 ).
Thus, the higher the K L /K H ratio before treatment, the lower the number of panic attacks and severity of anxiety and depression after treatment. Also, the higher the receptor density before treatment, the lower the severity of anxiety and depression after treatment.
DISCUSSION
To our knowledge, this is the first study in PD to examine parameters of ␣ 2 AR coupling and density in the high-and low-conformational states and agonist affinity to both states. Present results demonstrate upregulation of ␣ 2 AR density in PD, with trends for higher %R H and lower K L /K H ratio, putative indices of coupling to G i protein. Upregulation of receptor density in the highand low-conformational states contributed equally to this upregulation in total receptor density. When patients were subdivided based on their HAMD scores, upregulation in receptor density was more pronounced in patients with HAMD scores у15. Furthermore, these patients had significantly higher %R H and lower K L /K H ratio than healthy controls. There were no differences in agonist affinity to the receptor in either conformational state, although patients with HAMD scores у15 seemed to have lower agonist affinity to the receptor in the high-conformational state. Imipramine treatment had no effect on ␣ 2 AR binding parameters; however, high pretreatment ␣ 2 AR density and coupling were associated with low post-treatment symptom severity of anxiety and depression. Several interpretations may underlie ␣ 2 AR upregulation in PD. Upregulation in ␣ 2 AR density may be secondary to low NE levels or NE turnover rate, which is consistent with accumulating reports of low NE and/or MHPG levels in PD and other anxiety disorders (Hamlin et al. 1983; Edlund et al. 1987; Middleton et al. 1994; Murburg et al. 1994 Murburg et al. , 1995 Gurguis and Uhde 1998) .
However, given that the majority of studies reported normal plasma NE levels in PD (Cameron et al. 1984 (Cameron et al. , 1987 (Cameron et al. , 1990 (Cameron et al. , 1996 Albus et al. 1986; Schneider et al. 1987; Stein et al. 1992 ; Gurguis and Uhde 1998), failure in mechanisms involving agonist-mediated regulation of gene expression of adrenergic receptors (Hadcock and Malbon 1993, and references therein) may provide alternate, more plausible explanations for the present findings. Protein kinase A (PKA) is of particular interest, because it mediates agonist-induced receptor phosphorylation and downregulation. Upregulation of ␣ 2 AR density, therefore, may be attributable to abnormal PKA activity. Also, protein kinase C (PKC) has been shown to phosphorylate G i protein, to interfere with ␣ 2 AR-G i protein interaction, and to attenuate ␣ 2 AR- (Jakobs et al. 1985; Katada et al. 1985; García-Sáinz and Gutiérrez-Venegas 1989) . Under normal conditions, both %R H and the K L /K H ratio correlate positively with the agonist's intrinsic activity. Abnormal PKA and/or PKC activity also may explain the intriguing discrepancy found in PD patients in this study, wherein %R H was increased but the K L /K H ratio was decreased.
A third possible explanation is that upregulation of ␣ 2 AR density represents a compensatory mechanism for enhanced stimulatory input to the AC system through increased ␤AR function. ␣ 2 AR density correlates positively with ␤AR density (Falkay et al. 1994) . High intracellular cAMP levels increase the transcription rates of ␣ 2 AR, an effect that is mediated through the 5Ј promoter region of the ␣ 2 AR gene (Hadcock and Malbon 1993) . Also, stimulation of AC increases the expression of the inhibitory G i␣2 protein (Hadcock et al. 1990 ). Conversely, activation of the inhibitory input to AC is associated with increased ␤ 2 AR responsiveness and expression (Hadcock et al. 1991; Port et al. 1992 ). Increased ␣ 2 AR density, therefore, is consistent with results showing upregulation of ␤AR density and higher coupling to G s protein in PD (Albus et al. 1986; Gurguis et al. 1994 Gurguis et al. , 1997b .
The compensatory nature of upregulation of ␣ 2 AR density is consistent with findings in the present investigation showing that: (1) high anticipatory anxiety was associated with low ␣ 2 AR density; (2) high anxiety and depression ratings were associated with low K L /K H ratio; (3) high pretreatment K L /K H ratio was associated with a low number of panic attacks and severity of anxiety and depression at the end of treatment; and (4) high pretreatment receptor density was associated with low severity of anxiety and depression at the end of treatment.
High ␣ 2 AR density in PD is consistent with findings by Butler and colleagues (1992) , who found increased 3 H-rauwolscine maximum binding capacity in platelet membranes from PD patients. Vascular ␣ 2 AR mediate vasoconstriction and lack receptor reserve (Bolli et al. 1985; Nichols and Ruffolo 1991) . Increased ␣ 2 AR density, therefore, is consistent with enhanced ␣ 2 AR-mediated cardiovascular responses in PD patients (Nutt 1986 (Nutt , 1989 . Increased ␣ 2 AR density is not consistent with decreased 3 H-clonidine and 3 H-yohimbine binding to platelet ␣ 2 AR (Cameron et al. 1984 (Cameron et al. , 1990 (Cameron et al. , 1996 Albus et al. 1986 ) or with normal ␣ 2 AR density in PD mea- H-rauwolscine (Norman et al. 1987; Nutt and Fraser 1987; Charney et al. 1989) .
It seems that methodologic differences, other than the type of ligand used, may account for these discrepancies. Differences in the length of the drug wash-out period (which could not be ruled out in some studies), the blood collection procedure (such as the length of resting period before blood sampling), and gender (female PD patients may have higher catecholamine turnover rates and metabolite levels than males [Gurguis et al. 1991] ) could have contributed to the inconsistent results.
Electrophysiologic and receptor binding studies in rat brain have shown that various antidepressant treatment modalities (ECT, antidepressants, lithium) induce downregulation of ␣ 2 AR density. Some studies reported an increase in R H despite downregulation of total receptor density, suggesting that antidepressants enhance ␣ 2 AR-mediated inhibition of AC (Salama et al. 1982; Smith et al. 1983; Keith et al. 1986; Giralt and García-Sevilla 1989; Lacroix et al. 1991; Kovachich et al. 1993; Ribas et al. 1993; Moret and Briley 1994) . In this investigation, chronic treatment with imipramine at therapeutic doses was not associated with downregulation of ␣ 2 AR density either in the high-or low-conformational state. More importantly, chronic imipramine treatment had no effect on measures of ␣ 2 AR coupling to G i protein. This is consistent with the lack of effect of treatment with clomipramine and lofepramine on ␣ 2 AR density (Butler et al. 1992) , with the persistence of blunted growth hormone response to clonidine following prozac treatment in PD patients (Coplan et al. 1995) and following clorgyline, desipramine, or amitriptyline treatment in depressed patients (Charney et al. 1982; Siever et al. 1982) .
Clinical studies on the effects of antidepressants on platelet ␣ 2 AR in PD and depression have been inconsistent. Upregulation in ␣ 2 AR density was observed following imipramine treatment in PD (Cameron et al. 1984) . Downregulation in ␣ 2 AR density following antidepressant treatment in depression was observed only in some studies (García-Sevilla et al. 1981a ,b, 1986 Piletz and Halaris 1988; Piletz et al. 1991 Piletz et al. , 1993 , but not the majority (Lenox et al. 1983; Pimoule et al. 1983; Siever et al. 1983; Stahl et al. 1983; Campbell et al. 1985; Cooper et al. 1985; Katona et al. 1989; Pandey et al. 1989; Wolfe et al. 1989; Bhatia et al. 1991; Healy et al. 1991; Kaneko et al. 1992; Werstiuk et al. 1992) . Hence, the majority of studies on depression and two studies in PD did not find changes in ␣ 2 AR density in response to antidepressant treatment. It is reasonable, therefore, to conclude that upregulation of platelet ␣ 2 AR density may represent a link between the pathophysiology of PD and depression, which remains unchanged after antidepressant treatment. Increased platelet ␣ 2 AR density, therefore, may be a trait marker common to these related antidepressant-responsive disorders. Upregulation of ␣ 2 AR density in PD may also be related to the susceptibility of PD patients to major depression and to the notion that increased ␣ 2 AR density in PD is a trait marker.
It is worth noting that, despite the significant decrease in the total number of panic attacks after imipramine treatment, the decreases in post-treatment HAMA and HAMD scores were less than the conventionally acknowledged cut-off level of 50% decrease in severity of symptoms used to define successful treatment outcome. The small number of treated subjects in this study underscores the need to investigate antidepressant effects in a larger patient cohort. Our results do not address the likelihood of a decrease in post-treatment ␣ 2 AR density or change in coupling, had the decrease in HAMD scores been clinically significant. It is hypothetically likely that coupling parameters are different between treatment responders and nonresponders vis à vis healthy controls and that the effects of treatment on ␣ 2 AR coupling are different between treatment responders and nonresponders. Recent data from our laboratory have shown that depressed treatment nonresponsive patients have significantly lower ␣ 2 AR coupling, as compared to treatment-responsive patients (Gurguis et al. 1997a ). Alternatively, it is possible that the therapeutic effect (downregulation of receptor density or changes in receptor coupling) occurred in early phases of treatment (3-6 weeks) but readjusted later on. Also, in this study, imipramine had pronounced effects on mood, although it lacked a noticeable effect on somatic anxiety symptoms. The lack of effect on somatic anxiety symptoms may be consistent with the lack of effect on platelet ␣ 2 AR binding measures, further suggesting that upregulation in ␣ 2 AR density may be a trait marker in PD.
In both controls and PD patients, pretreatment % R H was positively correlated with severity of anxiety. However, the K L /K H ratio was positively correlated with severity of anxiety in healthy controls; whereas, it was negatively correlated with analogous measures in PD. This suggests a qualitative difference in the relationship between the K L /K H ratio and anxiety ratings in PD. In this study, we hypothesized abnormal ␣ 2 AR coupling to G i protein in PD, anticipating that both coupling indices would be either higher or lower than normal values. The finding in this study of significantly higher % R H , but lower K L /K H ratio, combined with the fact that the relationship between the K L /K H ratio and severity of anxiety was in an opposite direction to what was observed in controls, provide indirect evidence for abnormal PKC activity.
In summary, results of the present investigation demonstrate upregulation of ␣ 2 AR density and abnormal coupling to G i protein in PD. Abnormal coupling was more pronounced in symptomatically "depressed" patients. ␣ 2 AR upregulation suggests abnormal agonist regulation of ␣ 2 AR gene expression, possibly abnormal PKA or PKC activity. These results also demonstrate the lack of effect of antidepressant treatment on ␣ 2 AR and suggest that upregulation of ␣ 2 AR may be a trait marker in PD. Future studies should investigate the effect of antidepressant treatment on ␣ 2 AR coupling in relationship to treatment outcome. These future studies may identify possible predictors of treatment response and the effects of antidepressants on ␣ 2 AR coupling as related to treatment outcome. The role of PKA and PKC should also be subjects of future investigations in PD.
